Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - cukura diabēts, 2. tips - cukura diabēts - pacientiem ar 2. tipa cukura diabētu, tesavel ir norādīts, lai uzlabotu glycaemic kontrole:kā monotherapy:pacientiem nepietiekami kontrolēts ar diētu un vingrošanu, vieni un kuriem metformīns ir nevietā, jo kontrindikācijas vai nepanesamību;kā dual dobuma terapija kombinācijā ar:metformīns, kad diētu un vingrošanu, plus metformīns vien nenodrošina pietiekamu glycaemic kontrole;sulfonilurīnvielas pamata, kad diētu un vingrošanu, plus maksimālā pieļaujama devu sulfonilurīnvielas pamata, vien nenodrošina pietiekamu glycaemic kontroli un, ja metformīns ir nevietā, jo kontrindikācijas vai neiecietība;a ppary agonistu (i. a thiazolidinedione), kad izmantot ppary agonistu ir gadījumā un tad, ja diēta un fiziskā plus ppary agonistu vien nenodrošina pietiekamu glycaemic kontroli;kā triple dobuma terapija kombinācijā witha sulfonilurīnvielas pamata, un metformīns, kad diētu un vingrošanu, plus dual terapija ar šiem līdzekļiem, nenodrošina pietiekamu glycaemic kontrole;peroxisome-proliferator aktivizēts receptoru-gamma (ppary) agonistu un metformīns, kad izmantot ppary agonistu ir gadījumā un tad, ja diēta un fiziskā plus dual terapija ar šiem līdzekļiem, nenodrošina pietiekamu kontroles glycaemic. tesavel ir arī norādīts, kā pievienot uz insulīnu (ar vai bez metformīns) tad, ja diēta un fiziskā plus stabilu devu insulīna nenodrošina pietiekamu kontroles glycaemic.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - cukura diabēts, 2. tips - cukura diabēts - trajenta ir norādīts ārstēšanas 2. tipa cukura diabētu, lai uzlabotu glycaemic kontroles pieaugušajiem:kā monotherapyin pacienti nepietiekami kontrolēts ar diētu un vingrošanu, vieni un kuriem metformīns ir nevietā, jo neiecietība, vai kontrindicēta, jo nieru traucējumiem. kā kombinācija therapyin kombinācijā ar metformīnu, kad diētu un vingrošanu, plus metformīns vien nenodrošina pietiekamu kontroles glycaemic. kombinācijā ar sulfonilurīnvielas pamata, un metformīns, kad diētu un vingrošanu, plus dual terapija ar šīm zālēm nesniedz pienācīgu glycaemic kontrole. kombinācijā ar insulīnu, ar vai bez metformīns, kad šis režīms tikai ar diētu un vingrošanu, nenodrošina pietiekamu kontroles glycaemic.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antitrombotiskie līdzekļi - xigris tiek norādīts ārstēšana pieaugušiem pacientiem ar smagu sepse ar vairāku orgānu mazspēju, pievienojot standarta vislabāko iespējamo aprūpi. xigris lietošana galvenokārt jāņem vērā situācijās, kad terapiju var uzsākt 24 stundu laikā pēc orgānu mazspējas rašanās (plašāku informāciju skatīt apakšpunktā 5)..

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

lmp, sia, latvia - methyluracilum, lidocaini hydrochloridum - ziede - 5 mg/20 mg/g

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - pemetrekseds - pulveris infūziju šķīduma koncentrāta pagatavošanai - 500 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - pemetrekseds - pulveris infūziju šķīduma koncentrāta pagatavošanai - 100 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

hospira uk limited, united kingdom - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.